HOUSTON: Evotec AG has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures.
This initiative bridges the gap between basic science and advanced drug discovery by combining highly innovative research programs with state-of-the-art drug discovery capabilities and a private funding source committed to identifying new therapeutic approaches for Alzheimer’s disease. This collaboration initially leverages Evotec’s EVT Execute platform with defined options for transition into EVT Innovate programs.